Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows revision v3.4.2, replacing the previous v3.4.1. This is a minor metadata update that does not affect content, functionality, or user interactions.SummaryDifference0.1%

- Check20 days agoChange DetectedA minor revision label was updated from v3.4.0 to v3.4.1; no substantive study details or content were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedUI and copy updates include a glossary toggle, new labeling for 'Last Update Submitted that Met QC Criteria', and a Revision: v3.4.0, along with related FEAR Act data wording adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page. This is an administrative update to the version history and does not affect trial data, eligibility criteria, or study details.SummaryDifference0.1%

- Check63 days agoChange DetectedA new Locations section appears with Connecticut listed, replacing the older Connecticut Locations header; the HHS Vulnerability Disclosure footer link and the older revision label were removed.SummaryDifference0.2%

- Check91 days agoChange DetectedRevision: v3.3.2 added and Revision: v3.2.0 removed; this is a minor metadata update with no changes to study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.